We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.65B
Cap. Flow
% of AUM
97.21%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$91.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$79.7M |
| 3 |
Apple
AAPL
|
+$78.2M |
| 4 |
Qualcomm
QCOM
|
+$73.5M |
| 5 |
Amgen
AMGN
|
+$71.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.7% |
| 4 | Industrials | 8.01% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $84.5M | 1.77% |
+755,548
| New | +$79.7M |
|
|
2
Gilead Sciences
GILD
$165B
| $83.7M | 1.75% |
+888,125
| New | +$91.9M |
|
|
3
Apple
AAPL
$4.8T
| $79.3M | 1.66% |
+2,874,972
| New | +$78.2M |
|
|
4
Qualcomm
QCOM
$180B
| $74.7M | 1.56% |
+1,004,790
| New | +$73.5M |
|
|
5
Amgen
AMGN
$197B
| $73M | 1.53% |
+458,128
| New | +$71.4M |
|
6
ExxonMobil
XOM
$615B
| $65M | 1.36% |
+703,187
| New | +$65.6M |
|
7
Biogen
BIIB
$29.5B
| $63.8M | 1.33% |
+188,028
| New | +$60.8M |
|
8
Johnson & Johnson
JNJ
$599B
| $56.7M | 1.19% |
+542,266
| New | +$57.1M |
|
9
Pfizer
PFE
$141B
| $51M | 1.07% |
+1,726,960
| New | +$49.5M |
|
10
Intuit
INTU
$80.4B
| $50.9M | 1.06% |
+552,051
| New | +$49.1M |
|
11
Visa
V
$686B
| $49.5M | 1.03% |
+755,052
| New | +$45.5M |
|
12
Alphabet (Google) Class C
GOOG
$4.29T
| $48.2M | 1.01% |
+1,827,504
| New | +$49M |
|
13
Merck
MRK
$307B
| $47.1M | 0.98% |
+868,459
| New | +$48.4M |
|
14
Parker-Hannifin
PH
$120B
| $45.3M | 0.95% |
+351,178
| New | +$43.1M |
|
15
Microsoft
MSFT
$2.99T
| $41.6M | 0.87% |
+896,160
| New | +$42.1M |
|
16
Verizon
VZ
$182B
| $41.1M | 0.86% |
+878,709
| New | +$43M |
|
17
Berkshire Hathaway Class B
BRK.B
$1.06T
| $39.9M | 0.83% |
+265,952
| New | +$38.4M |
|
18
American Express
AXP
$240B
| $39.8M | 0.83% |
+428,280
| New | +$38.4M |
|
19
Coca-Cola
KO
$353B
| $39.8M | 0.83% |
+943,774
| New | +$40.3M |
|
20
AbbVie
ABBV
$448B
| $36.8M | 0.77% |
+562,971
| New | +$35.5M |
|
21
Cigna
CI
$75.1B
| $36.8M | 0.77% |
+357,735
| New | +$35.3M |
|
22
AT&T
T
$153B
| $36.7M | 0.77% |
+1,444,816
| New | +$37.5M |
|
23
Meta Platforms (Facebook)
META
$1.64T
| $36.2M | 0.76% |
+463,640
| New | +$35.4M |
|
24
iShares MSCI Japan ETF
EWJ
$21.6B
| $36.1M | 0.76% |
+803,784
| New | +$36.9M |
|
25
Colgate-Palmolive
CL
$73.6B
| $36.1M | 0.75% |
+521,760
| New | +$35.2M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Candriam SCA, which disclosed 616 positions worth $4.78B. Its ten largest holdings account for 14% of the portfolio.
Its largest position is Gilead Sciences: 888,125 shares worth $83.7M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Financials and Technology.
- Candriam SCA's largest Q4 2014 buy was Gilead Sciences: 888,125 shares worth $83.7M.
- Candriam SCA's ten largest holdings make up 14% of its $4.78B portfolio in Q4 2014.
- Candriam SCA disclosed 616 positions in Q4 2014, its first 13F filing on record.
Based on Candriam SCA's 13F filing for Q4 2014, filed 26 Mar 2015.